A Phase 2, Multicenter, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Known or Suspected to be Due to Gram-positive Organisms

Trial Profile

A Phase 2, Multicenter, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Known or Suspected to be Due to Gram-positive Organisms

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Osteomyelitis
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 18 Sep 2017 Status changed from recruiting to discontinued.
    • 05 May 2017 Status changed from not yet recruiting to recruiting.
    • 29 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top